# US 10,768,167 B2 · Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,768,167 B2
- Document ID: US10768167B2
- Status: Granted
- Kind: B2
- Application number: 15/514,255
- Filed: 2015-09-25
- Published: 2017-08-24
- Granted: 2020-09-08
- Earliest claimed: 2014-09-25
- Assignees: Universitätsklinikum Regensburg
- Applicants: Universitätsklinikum Regensburg
- Inventors: Edward Geissler; Maria Mycielska; Petra Rümmele
- Web page: https://patentgrep.com/patent/US10768167B2

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- C07K 16/18: against material from animals or humans
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/158: Expression markers
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to a method for the diagnosis of cancer involving the plasma membrane citrate transporter (pmCiC). The invention is further directed to a modified substrate or modulator of pmCiC, the use of pmCiC as a tumor marker and a method of screening for a modulator of pmCiC activity.

## Claims

### Claim 1

A method of treating cancer in a patient in need thereof, the method comprising administering to the patient an inhibitor of plasma membrane citrate transporter (pmCiC) activity, wherein said cancer is selected from the group consisting of prostate cancer, gastric cancer, pancreatic cancer, breast cancer, and colon cancer and wherein said inhibitor of pmCiC activity is gluconate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment comprises administering gluconate to a cancer patient in a physiologically suitable dosage form, thereby promoting cancer cell death.